ArticleRevista clinica espanola2022
[CURB-65 as a predictor of 30-day mortality in patients hospitalized with COVID-19 in Ecuador: COVID-EC study].
Article in Revista clinica espanola, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 18 citations in OpenAlex.
- Predictability of Severity Scores in Patients over 70 Years Old with COVID-19 Infection: Results from a Single-Center Retrospective Observational Study.Journal of clinical medicine · 2026Article
- Risk model derivation and clinical outcomes in COVID-19 pneumonia patients discharged from the emergency department.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Article
- Prognostication of COVID-19 patients using ROX index and CURB-65 score - A retrospective observational study.Journal of family medicine and primary care · 2022Article
- [Predicting COVID-19 progress with clinical scales].Revista clinica espanola · 2022Article
- Predicting COVID-19 progress with clinical scales.Revista clinica espanola · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis article aims to assess the utility of CURB-65 in predicting 30-day mortality in adult patients hospitalized with COVID-19.
methodsThis work is a cohort study conducted between March 1 and April 30, 2020 in Ecuador.
resultsA total of 247 patients were included (mean age 60 ± 14 years, 70% men, overall mortality 41.3%). Patients with CURB-65 ≥ 2 had a higher mortality rate (57 vs. 17%,
conclusionsCURB-65 ≥ 2 was associated with higher 30-day mortality on the univariate (Kaplan-Meier estimator) and multivariate (Cox regression) analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.